Laboratory of Biochemistry, Department of Biopharmaceutical Sciences, Gifu Pharmaceutical University, Gifu, Japan.
School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Biochim Biophys Acta Mol Cell Res. 2018 Mar;1865(3):470-479. doi: 10.1016/j.bbamcr.2017.12.005. Epub 2017 Dec 13.
Claudins, tight junctional proteins, regulate the paracellular permeability of ions and small molecules. Claudin-2 is highly expressed in human lung adenocarcinoma cells and is involved in the up-regulation of cell proliferation. However, the effect of claudin-2 on cellular sensitivity to anticancer agents has not been clarified. The cytotoxicity of anticancer agents such as cisplatin, gefitinib and doxorubicin (DXR) was increased by claudin-2 knockdown in A549 cells. Claudin-2 knockdown also significantly decreased the expression level of multidrug resistance-associated protein/ABCC2. The expression levels of other drug efflux transporters were unchanged. The intracellular accumulation of 5-chloromethylfluorescein diacetate (CMFDA) and DXR, substrates of ABCC2, was increased by claudin-2 knockdown, whereas the efflux was decreased. MK-571, an inhibitor of ABCC2, enhanced the cytotoxicity of anticancer agents. Claudin-2 knockdown decreased the levels of p-c-Jun and nuclear Sp1. SP600125, an inhibitor of c-Jun, and mithramycin, an inhibitor of Sp1, decreased the level of ABCC2. The promoter activity of ABCC2 was decreased by claudin-2 knockdown, SP600125 and mithramycin treatments, suggesting that claudin-2 is involved in the up-regulation of ABCC2 expression at the transcriptional level. Claudin-2 knockdown increased the paracellular permeability of DXR in a 2D monolayer culture model. In addition, the accumulation of DXR into spheroids was enhanced by claudin-2 knockdown, resulting in a reduction in cell viability. We suggest that claudin-2 may be a novel therapeutic target in lung adenocarcinoma, because claudin-2 knockdown increased the accumulation of anticancer agents in cancer cells and spheroids.
紧密连接蛋白 Claudin-2 调节离子和小分子的细胞旁通透性。Claudin-2 在人肺腺癌细胞中高表达,并参与细胞增殖的上调。然而,Claudin-2 对细胞对抗癌药物敏感性的影响尚未阐明。Claudin-2 敲低可增加 A549 细胞中顺铂、吉非替尼和阿霉素(DXR)等抗癌药物的细胞毒性。Claudin-2 敲低还显著降低了多药耐药相关蛋白/ABCC2 的表达水平。其他药物外排转运蛋白的表达水平不变。ABCC2 底物 5-氯甲基荧光素二乙酸酯(CMFDA)和 DXR 的细胞内积累通过 Claudin-2 敲低而增加,而外排则减少。ABCC2 的抑制剂 MK-571 增强了抗癌药物的细胞毒性。Claudin-2 敲低降低了 p-c-Jun 和核 Sp1 的水平。c-Jun 的抑制剂 SP600125 和 Sp1 的抑制剂米托霉素降低了 ABCC2 的水平。Claudin-2 敲低、SP600125 和米托霉素处理降低了 ABCC2 的启动子活性,表明 Claudin-2 参与了 ABCC2 表达的转录水平上调。Claudin-2 敲低增加了 2D 单层培养模型中 DXR 的细胞旁通透性。此外,Claudin-2 敲低增强了 DXR 进入球体的积累,导致细胞活力降低。我们认为 Claudin-2 可能是肺腺癌的一种新的治疗靶点,因为 Claudin-2 敲低增加了抗癌药物在癌细胞和球体中的积累。